About
Efficacy
Safety
Dosing
Support & Resources
Information on how to access Cibinqo®▼ (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.
Cibinqo – a new, once daily, oral option to take on the variability of your patients' atopic dermatitis (AD)
For patients aged 12 years and older with moderate-to-severe AD who are candidates for systemic therapy1
Cibinqo is an oral JAK inhibitor that can offer your patients:1–4
|
|
CONTROLSignificant skin clearance vs placebo at Week 12,*2–4 with sustained control through Week 48†1. Review clinical trials within 'Efficacy' section. |
SPEEDRapid itch relief with Cibinqo 200 mg superior to dupilumab at Week 2 in the proportion of patients achieving PP-NRS4 (49.1% vs 26.4% abrocitinib 200mg vs dupilumab respectively),2 with higher itch response seen as early as Day 4 after the first dose‡1. Review clinical trials within 'Efficacy' section. |
|
FLEXIBILITYPatients can benefit from the option to start on 200 mg or 100 mg§. During treatment the dose may be increased or decreased to meet the needs of your patients1. Review 'Dosing' section for further information. |
Explore more
MOA overview
Learn more about JAK inhibition, the role of the JAK/STAT pathway and how Cibinqo works.
Patient profiles
Discover which patients may be suitable for treatment with Cibinqo.
*In JADE MONO-1 and MONO-2 (monotherapy), a significantly higher proportion of patients achieved EASI-75 at Week 12 with Cibinqo 200 mg (62.7%; 61.0%) and Cibinqo 100 mg (39.7%; 44.5%), compared with placebo (11.8%; 10.4% [P<0.0001 for both doses vs placebo]). In COMPARE, when used in combination with medicated topical therapy, EASI-75 response at Week 12 was observed in 70.3% of patients in the Cibinqo 200 mg group, 58.7% in Cibinqo 100 mg, and 27.1% in placebo (P<0.001 for both doses vs placebo).
†Among patients who achieved EASI-75 after 12 weeks of treatment and entered JADE EXTEND, 71% and 69% of patients in the Cibinqo 200 mg and 100 mg groups maintained EASI-75 at Week 48, respectively.
‡In JADE COMPARE, Cibinqo 200 mg was compared with dupilumab in the key secondary head-to-head endpoint, PP-NRS4 at Week 2. This endpoint was further analysed as a prespecified multiplicity-controlled analysis and showed superiority to dupilumab down to Day 4. PP-NRS4 response is defined as a 4 or greater reduction in itch score from baseline on a scale of 0 to 10.
§For most patients, particularly those with severe disease, the recommended starting dose is 200 mg. A dose of 100 mg once daily is the recommended starting dose for patients aged ≥65 years, adolescents (12–17 years old), and for those who have risk factors for developing an adverse reaction to Cibinqo or those who are less likely to tolerate the adverse reactions. The maximum dose of Cibinqo is 200 mg once daily.
Prescribing information:
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 200 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 100 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 50 mg film-coated tablets.
Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Card.
For UK Healthcare Professionals*
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
No